HRR Testing Podcast
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer

Released: March 28, 2024

Expiration: March 27, 2025

Heather H. Cheng
Heather H. Cheng, MD, PhD
Colin C. Pritchard
Colin C. Pritchard, MD, PhD

Activity

Progress
1
Course Completed

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including:

  • Rationale for targeting PARP in prostate cancer with ARI combinations
  • Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2
  • FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on mutations
  • Optimal biomarker testing for gene mutations in homologous recombination and mismatch repair pathways
  • Tips for optimal coordination between pathology and medical oncology